MX2016016722A - Coronavirus. - Google Patents
Coronavirus.Info
- Publication number
- MX2016016722A MX2016016722A MX2016016722A MX2016016722A MX2016016722A MX 2016016722 A MX2016016722 A MX 2016016722A MX 2016016722 A MX2016016722 A MX 2016016722A MX 2016016722 A MX2016016722 A MX 2016016722A MX 2016016722 A MX2016016722 A MX 2016016722A
- Authority
- MX
- Mexico
- Prior art keywords
- nsp
- coronavirus
- vaccine
- mutation
- live
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1413020.7A GB201413020D0 (en) | 2014-07-23 | 2014-07-23 | Coronavirus |
PCT/GB2015/052124 WO2016012793A1 (en) | 2014-07-23 | 2015-07-23 | Coronavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016016722A true MX2016016722A (es) | 2017-04-13 |
Family
ID=51494985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016016722A MX2016016722A (es) | 2014-07-23 | 2015-07-23 | Coronavirus. |
Country Status (17)
Country | Link |
---|---|
US (1) | US10130701B2 (enAs) |
EP (2) | EP3656856B1 (enAs) |
JP (1) | JP6712268B2 (enAs) |
KR (1) | KR20170032441A (enAs) |
CN (1) | CN106536723A (enAs) |
AU (1) | AU2015293633B2 (enAs) |
BR (1) | BR112017001310B1 (enAs) |
CA (1) | CA2953677C (enAs) |
DK (1) | DK3172319T3 (enAs) |
ES (1) | ES2764275T3 (enAs) |
GB (1) | GB201413020D0 (enAs) |
HU (1) | HUE047953T2 (enAs) |
IL (1) | IL249340A0 (enAs) |
MX (1) | MX2016016722A (enAs) |
PL (1) | PL3172319T3 (enAs) |
PT (1) | PT3172319T (enAs) |
WO (1) | WO2016012793A1 (enAs) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019018251A2 (pt) * | 2017-03-03 | 2020-06-23 | Loyola University Chicago | Coronavírus, vacinas compreendendo os mesmos, e métodos para a prevenção de doença |
JP7350864B2 (ja) * | 2018-10-31 | 2023-09-26 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 異種スパイクタンパク質を有するh52 ibvワクチン |
KR102119875B1 (ko) * | 2019-03-19 | 2020-06-05 | 한국화학연구원 | 한국형 중동호흡기증후군 코로나바이러스 감염성 변이 유전자 및 이의 용도 |
EP3966318A1 (en) * | 2019-05-10 | 2022-03-16 | Boehringer Ingelheim Vetmedica GmbH | Attenuated ibv with extended cell culture and tissue tropism |
CN111254155A (zh) * | 2020-01-25 | 2020-06-09 | 王跃驹 | 一种植物作为宿主表达病毒疫苗的方法 |
KR20220151168A (ko) | 2020-02-09 | 2022-11-14 | 엔엘씨 파르마 엘티디 | Sars-cov-2에 대한 신속한 검출 테스트 |
CN115884785A (zh) * | 2020-03-23 | 2023-03-31 | 芝加哥罗约拉大学 | 冠状病毒疫苗组合物及其使用方法 |
WO2021203236A1 (zh) * | 2020-04-07 | 2021-10-14 | 四川骋誉生物制品有限公司 | 用于预防covid-19的蝙蝠源性冠状病毒疫苗 |
CN116348477A (zh) | 2020-07-20 | 2023-06-27 | 英安塔制药有限公司 | 作为抗病毒剂的功能化肽 |
CN112029781B (zh) * | 2020-08-14 | 2023-01-03 | 中山大学 | 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用 |
JP2024004496A (ja) * | 2020-10-14 | 2024-01-17 | 一般財団法人阪大微生物病研究会 | ノックアウトコロナウイルス |
EP4247387A1 (en) | 2020-11-23 | 2023-09-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US11384090B2 (en) | 2020-11-23 | 2022-07-12 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
US11352363B1 (en) | 2020-11-23 | 2022-06-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
CN112592905B (zh) * | 2020-12-28 | 2023-07-28 | 广州达安基因股份有限公司 | 用于新型冠状病毒检测的dna聚合酶混合物 |
CN114751964B (zh) * | 2020-12-29 | 2024-03-08 | 苏州方舟生物科技有限公司 | β属冠状病毒通用疫苗蛋白片段及其筛选方法和应用 |
WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
US11319325B1 (en) | 2021-05-11 | 2022-05-03 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
CN113308440B (zh) * | 2021-05-26 | 2023-04-28 | 武汉大学 | 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用 |
US11339170B1 (en) | 2021-07-23 | 2022-05-24 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
US11325916B1 (en) | 2021-07-29 | 2022-05-10 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
WO2023049300A1 (en) * | 2021-09-22 | 2023-03-30 | Biomedit, Llc | Methods of inhibiting diseases caused by respiratory viruses |
US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE445412T1 (de) | 2003-03-03 | 2009-10-15 | Intervet Int Bv | Ein virus der infektiösen bronchitis mit veränderten spike-gen |
EP1618127B1 (en) | 2003-04-10 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic composition comprising a spike protein of the SARS coronavirus |
EP1533370A1 (en) | 2003-11-18 | 2005-05-25 | ViroNovative B.V. | Novel atypical pneumonia-causing virus |
CN100413537C (zh) * | 2004-01-29 | 2008-08-27 | 国家人类基因组南方研究中心 | Sars冠状病毒全病毒疫苗 |
US7452542B2 (en) * | 2004-05-21 | 2008-11-18 | Vanderbilt University | Live attenuated coronavirus vaccines |
WO2007078203A1 (en) | 2006-01-03 | 2007-07-12 | Norwex Holding As | Anti-bacterial micro-fibre and production thereof |
GB0911794D0 (en) | 2009-07-07 | 2009-08-19 | Animal Health Inst | Chimaeric protein |
CN102851257A (zh) * | 2012-08-27 | 2013-01-02 | 上海启盛生物科技有限公司 | 一种鸡传染性支气管炎病毒减毒疫苗株及其应用 |
CN103397002A (zh) * | 2013-08-07 | 2013-11-20 | 广东温氏食品集团股份有限公司 | 禽传染性支气管炎病毒的致弱方法 |
-
2014
- 2014-07-23 GB GBGB1413020.7A patent/GB201413020D0/en not_active Ceased
-
2015
- 2015-07-23 MX MX2016016722A patent/MX2016016722A/es active IP Right Grant
- 2015-07-23 JP JP2017524123A patent/JP6712268B2/ja active Active
- 2015-07-23 ES ES15750093T patent/ES2764275T3/es active Active
- 2015-07-23 KR KR1020177004614A patent/KR20170032441A/ko not_active Application Discontinuation
- 2015-07-23 EP EP19208113.1A patent/EP3656856B1/en active Active
- 2015-07-23 PT PT157500935T patent/PT3172319T/pt unknown
- 2015-07-23 AU AU2015293633A patent/AU2015293633B2/en not_active Ceased
- 2015-07-23 US US15/328,179 patent/US10130701B2/en active Active
- 2015-07-23 PL PL15750093T patent/PL3172319T3/pl unknown
- 2015-07-23 CA CA2953677A patent/CA2953677C/en active Active
- 2015-07-23 BR BR112017001310-0A patent/BR112017001310B1/pt active IP Right Grant
- 2015-07-23 WO PCT/GB2015/052124 patent/WO2016012793A1/en active Application Filing
- 2015-07-23 CN CN201580037402.1A patent/CN106536723A/zh active Pending
- 2015-07-23 EP EP15750093.5A patent/EP3172319B1/en active Active
- 2015-07-23 HU HUE15750093A patent/HUE047953T2/hu unknown
- 2015-07-23 DK DK15750093.5T patent/DK3172319T3/da active
-
2016
- 2016-12-01 IL IL249340A patent/IL249340A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2764275T3 (es) | 2020-06-02 |
PL3172319T3 (pl) | 2020-06-29 |
US20170216427A1 (en) | 2017-08-03 |
JP6712268B2 (ja) | 2020-06-17 |
GB201413020D0 (en) | 2014-09-03 |
BR112017001310B1 (pt) | 2022-06-28 |
US10130701B2 (en) | 2018-11-20 |
CA2953677A1 (en) | 2016-01-28 |
EP3656856A1 (en) | 2020-05-27 |
AU2015293633B2 (en) | 2021-04-08 |
CA2953677C (en) | 2023-09-26 |
EP3172319A1 (en) | 2017-05-31 |
WO2016012793A1 (en) | 2016-01-28 |
DK3172319T3 (da) | 2020-02-03 |
CN106536723A (zh) | 2017-03-22 |
BR112017001310A2 (pt) | 2018-04-17 |
KR20170032441A (ko) | 2017-03-22 |
EP3656856B1 (en) | 2021-10-20 |
AU2015293633A1 (en) | 2016-12-15 |
HUE047953T2 (hu) | 2020-05-28 |
PT3172319T (pt) | 2020-01-14 |
EP3172319B1 (en) | 2019-11-20 |
IL249340A0 (en) | 2017-02-28 |
JP2017522907A (ja) | 2017-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016016722A (es) | Coronavirus. | |
PH12015502790A1 (en) | Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof | |
PH12016502468A1 (en) | Influenza virus vaccines and uses thereof | |
PH12019502010A1 (en) | Coronaviruses, vaccines comprising the same, and methods for preventing disease | |
MX2017001406A (es) | Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva. | |
EA201890527A1 (ru) | Терапевтические вакцины против hpv18 | |
MX2017002803A (es) | Coronavirus bovino atenuado y vacunas relacionadas. | |
EA201692541A1 (ru) | Вакцины против вируса гриппа и их применения | |
MX2021010060A (es) | Produccion de virus en huevos aviares. | |
PH12018501154A1 (en) | Attenuated infectious bronchitis virus | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
MX2014006630A (es) | Vacuna a base toxina clostridium difficile. | |
PH12016502002A1 (en) | Novel bacteriophage and composition comprising same | |
BR112018012642A2 (pt) | vacina de calicivírus felino | |
MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
MX2018006416A (es) | Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina. | |
MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
MX2018014955A (es) | Vacunas atenuadas vivas del virus de la influenza equina. | |
PH12017501100A1 (en) | Recombinant swinepox virus and vaccines | |
NZ728041A (en) | Substances and methods for the use in prevention and/or treatment in huntington’s disease | |
IL259451B (en) | A live virus containing an attenuated dengue virus and a dengue vaccine containing identical antigens | |
AR101731A1 (es) | Coronavirus bovino atenuado y vacunas relacionadas | |
MA39900A (fr) | Vaccins à base d'acide nucléique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |